Baxalta Inc., of Bannockburn, Ill., reported that Adynovate (antihemophilic factor [recombinant], pegylated) successfully met its primary endpoint in a phase III study designed to assess the safety and immunogenicity of the hemophilia A therapy, which gained FDA approval in November.